Statin use linked to reduction in risks for all-cause dementia and Alzheimer disease-related dementia
WEDNESDAY, April 9, 2025 (HealthDay News) — Low low-density lipoprotein cholesterol (LDL-C) levels are associated with a reduced risk for dementia, including Alzheimer disease-related dementia (ADRD), according to a study published online April 1 in the Journal of Neurology, Neurosurgery & Psychiatry.
Minwoo Lee, M.D., Ph.D., from Hallym University College of Medicine in Anyang, South Korea, and colleagues examined the association between low LDL-C levels and the risk for dementia and assessed the influence of statin therapy in a retrospective analysis of data from 11 university hospitals participating in the Observational Medical Outcomes Partnership Common Data Model. A primary analysis cohort of 108,980 propensity score-matched patients compared individuals with LDL-C levels less than 70 mg/dL to those with levels greater than 130 mg/dL.
The researchers found a 26 percent reduction in the risk for all-cause dementia and a 28 percent reduction in the risk for ADRD in association with LDL-C levels below 70 mg/dL versus greater than 130 mg/dL. An 18 percent risk reduction for both outcomes was seen for LDL-C levels below 55 mg/dL. Statin use versus nonuse was associated with a 13 and 12 percent reduction in the risks for all-cause dementia and ADRD, respectively.
“These findings underscore the crucial role of managing LDL-C in lowering dementia risk and highlight the importance of targeted strategies in addressing cardiovascular and cognitive health outcomes by physicians,” the authors write.
Voice Disorders Linked to Elevated Risk for Incident Cognitive Decline
Dementia, Stroke Risk Elevated for Those With Severe Mental Illness
NOACs Linked to Slower Cognitive Decline in Patients With A-Fib, Alzheimer Disease
Cortical Atrophy in Early-Onset Alzheimer Disease Signature Can Predict Progression to Dementia
Brain Abnormalities Identified in Children at Risk for Schizophrenia
Exercise Link to Dementia Varies by Physical Activity Domain
Real-World ARIA Incidence With Lecanemab Aligns With Clinical Trial Findings